These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19139476)

  • 81. Pharmacogenomic-guided dosing for warfarin: too little too late?
    Wu AH
    Per Med; 2018 Mar; 15(2):71-73. PubMed ID: 29714120
    [No Abstract]   [Full Text] [Related]  

  • 82. In silico pharmacogenetics of warfarin metabolism.
    Guo Y; Weller P; Farrell E; Cheung P; Fitch B; Clark D; Wu SY; Wang J; Liao G; Zhang Z; Allard J; Cheng J; Nguyen A; Jiang S; Shafer S; Usuka J; Masjedizadeh M; Peltz G
    Nat Biotechnol; 2006 May; 24(5):531-6. PubMed ID: 16680137
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine?
    Enchin H
    AMIA Annu Symp Proc; 2009 Nov; 2009():168-72. PubMed ID: 20351843
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pharmacogenetics in Jewish populations.
    Yang Y; Peter I; Scott SA
    Drug Metabol Drug Interact; 2014; 29(4):221-33. PubMed ID: 24867283
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacogenetics: from discovery to patient care.
    Shin J; Kayser SR; Langaee TY
    Am J Health Syst Pharm; 2009 Apr; 66(7):625-37. PubMed ID: 19299369
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Implementation of inpatient models of pharmacogenetics programs.
    Cavallari LH; Lee CR; Duarte JD; Nutescu EA; Weitzel KW; Stouffer GA; Johnson JA
    Am J Health Syst Pharm; 2016 Dec; 73(23):1944-1954. PubMed ID: 27864202
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.
    Allyn-Feuer A; Ade A; Luzum JA; Higgins GA; Athey BD
    Pharmacogenomics; 2018 Apr; 19(5):413-434. PubMed ID: 29400612
    [TBL] [Abstract][Full Text] [Related]  

  • 88. More on pharmacogenomics and warfarin.
    Anderson DC
    Am J Health Syst Pharm; 2009 Jul; 66(14):1256-7. PubMed ID: 19574598
    [No Abstract]   [Full Text] [Related]  

  • 89. A systems approach to designing effective clinical trials using simulations.
    Fusaro VA; Patil P; Chi CL; Contant CF; Tonellato PJ
    Circulation; 2013 Jan; 127(4):517-26. PubMed ID: 23261867
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical relevance of pharmacogenetics.
    Becquemont L
    Drug Metab Rev; 2003 Nov; 35(4):277-85. PubMed ID: 14705861
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Mapping genes that predict treatment outcome in admixed populations.
    Baye TM; Wilke RA
    Pharmacogenomics J; 2010 Dec; 10(6):465-77. PubMed ID: 20921971
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time.
    Eby CS
    Clin Chem; 2009 Apr; 55(4):712-4. PubMed ID: 19233915
    [No Abstract]   [Full Text] [Related]  

  • 93. Ethnic Diversity and Warfarin Pharmacogenomics.
    Asiimwe IG; Pirmohamed M
    Front Pharmacol; 2022; 13():866058. PubMed ID: 35444556
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective.
    Drozda K; Pacanowski MA; Grimstein C; Zineh I
    JACC Basic Transl Sci; 2018 Aug; 3(4):545-549. PubMed ID: 30175278
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease.
    Al-Eitan LN; Elsaqa BZ; Almasri AY; Aman HA; Khasawneh RH; Alghamdi MA
    Pharmgenomics Pers Med; 2020; 13():619-632. PubMed ID: 33235484
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comment on 'Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized clinical trials' by Tse et al.
    Sridharan K; Sequeira RP
    Br J Clin Pharmacol; 2018 Sep; 84(9):2162-2164. PubMed ID: 29876946
    [No Abstract]   [Full Text] [Related]  

  • 97. Reply to 'Comment on 'Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized clinical trials' by Tse et al.'.
    Tse G; Roever L; Wong MCS; Lip GYH; Liu T;
    Br J Clin Pharmacol; 2018 Sep; 84(9):2165-2166. PubMed ID: 29984539
    [No Abstract]   [Full Text] [Related]  

  • 98. Genomic medicine in Africa: a need for molecular genetics and pharmacogenomics experts.
    Oluwole OG; Henry M
    Curr Med Res Opin; 2023 Jan; 39(1):141-147. PubMed ID: 36094413
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Interactions of warfarin with drugs and food.
    Wells PS; Holbrook AM; Crowther NR; Hirsh J
    Ann Intern Med; 1994 Nov; 121(9):676-83. PubMed ID: 7944078
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Using multiple drug exposure levels to optimize power in pharmacogenetic trials.
    Judson R
    J Clin Pharmacol; 2003 Aug; 43(8):816-24. PubMed ID: 12953338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.